# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Preliminary Results On October 6, 2024, the Company reported the following preliminary unaudited fiscal year 2025 financial an...
Maxim Group analyst Anthony Vendetti initiates coverage on NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy rating and announc...
-SEC Filing
NeuroOne Medical Tech (NASDAQ:NMTC) affirms FY2025 sales outlook from $8.00 million-$10.00 million to $8.00 million-$10.00 mill...
NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of...